Sara M Federico
Children's Oncology Group · St. Jude Children's Research Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sara M Federico as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:47 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06172296 · Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaNational Cancer Institute (NCI) · recruiting · Ganglioneuroblastoma, Nodular, Neuroblastoma · principal investigator
- Ph2NCT03786783 · Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaNational Cancer Institute (NCI) · completed · Ganglioneuroblastoma, High Risk Neuroblastoma · principal investigator
- Ph1NCT02392793 · Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid MalignanciesSt. Jude Children's Research Hospital · completed · Childhood Solid Tumors · principal investigator
- Ph2NCT01946529 · Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell TumorsSt. Jude Children's Research Hospital · completed · Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · principal investigator
- Ph2NCT01857934 · Therapy for Children With Advanced Stage NeuroblastomaSt. Jude Children's Research Hospital · completed · Neuroblastoma · principal investigator
- N/ANCT01050296 · Molecular Analysis Of Solid TumorsSt. Jude Children's Research Hospital · recruiting · Pediatric Solid Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026Named on NCT06172296, NCT03786783
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:47 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.Clin Cancer Res · 2017133 citationsRCR 4.1
- Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.J Clin Oncol · 202294 citationsRCR 6.6
- A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma.Clin Cancer Res · 201975 citationsRCR 2.8
- A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.Eur J Cancer · 202066 citationsRCR 2.5
- Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial.Lancet Infect Dis · 201849 citationsRCR 3.3
- A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.Oncotarget · 201624 citationsRCR 0.7
- Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial.J Immunother Cancer · 202022 citationsRCR 0.9
- Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.Eur J Cancer · 201621 citationsRCR 0.7
- 14 citationsRCR 0.7